Carisma Therapeutics Inc.

66 articles about Carisma Therapeutics Inc.

• Carisma Therapeutics to Present at Upcoming Investor Conferences in June 2023

  6/5/2023

  Carisma Therapeutics Inc. today announced that the Company will present at several investor conferences in June 2023.

• Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in June 2023

  5/30/2023

  Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will present at several healthcare industry conferences in June 2023.

• Carisma Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

  5/11/2023

  Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the first quarter ended March 31, 2023 and provided business highlights.

• Carisma Therapeutics to Present at the JMP Securities Life Sciences Conference - May 08, 2023

  5/8/2023

  Carisma Therapeutics Inc. announced that Steven Kelly, President and Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Monday, May 15 at 1:00 pm EDT in New York.

• Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in May 2023

  5/5/2023

  Carisma Therapeutics Inc. today announced that the company will present at several healthcare industry conferences in May 2023.

• Carisma Therapeutics to Present at The American Association for Cancer Research Annual Meeting

  4/14/2023

  Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced three abstracts were accepted for presentation at The American Association for Cancer Research (AACR) Annual Meeting held from Friday, April 14 – Wednesday, April 19 in Orlando, FL.

• Carisma Therapeutics to Present at Upcoming Healthcare Industry and Investor Conferences in April 2023

  4/6/2023

  Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will participate at several conferences in April 2023.

• Carisma Therapeutics Reports Fiscal 2022 Financial Results and Recent Business Highlights

  4/4/2023

  Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the year ended December 31, 2022 and highlighted recent business updates.

• Carisma Therapeutics Closes Merger with Sesen Bio

  3/7/2023

  Carisma Therapeutics Inc. and Sesen Bio, Inc. ("Sesen Bio"), announced today the closing of their previously announced merger.

• Sesen Bio Stockholders Approve Merger with Carisma Therapeutics

  3/2/2023

  Sesen Bio, Inc., announced that its stockholders have voted to approve all proposals, including the pending merger with Carisma Therapeutics Inc., at the Company’s Special Meeting of Stockholders.

• Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger

  2/16/2023

  Sesen Bio, Inc. announced that members of its management team will host a fireside chat with members of the Carisma Therapeutics Inc. management team on Tuesday, February 21, 2023, at 8:00 am ET.

• BML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics

  2/15/2023

  Sesen Bio, Inc., announced that BML Investment Partners, L.P., one of Sesen Bio’s top stockholders, intends to vote all of its shares in support of the Company’s pending merger with Carisma Therapeutics Inc.

• Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger

  2/14/2023

  Sesen Bio, Inc. and Carisma Therapeutics Inc. announced that the companies have reached a voting and support agreement with Bradley L. Radoff and Michael Torok.

• Carisma Therapeutics Appoints Moderna CSO of External Research Ventures, Lin Guey, to Scientific Advisory Board

  2/7/2023

  Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced the appointment of Lin Guey, PhD to the company's Scientific Advisory Board (SAB).

• Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger

  2/2/2023

  Sesen Bio, Inc. filed an investor presentation highlighting its value maximizing merger with Carisma Therapeutics Inc.

• Carisma Therapeutics Appoints Leading Solid Tumor Immunotherapy Expert Padmanee Sharma, MD, PhD to Scientific Advisory Board

  1/31/2023

  Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced the appointment of Padmanee Sharma, MD, PhD to the company's Scientific Advisory Board (SAB).

• Sesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of Stockholders

  1/26/2023

  Sesen Bio, Inc. (Nasdaq: SESN) today issued the following statement reiterating the Company’s confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. (Carisma) in response to the release issued yesterday by Bradley Radoff and Michael Torok and their affiliates (collectively, the “Investor Group”).

• Sesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma Therapeutics

  1/19/2023

  Sesen Bio, Inc. announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the Company’s pending merger with Carisma Therapeutics Inc., a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies.

• Sesen Bio Reiterates Confidence in Pending Merger with Carisma Therapeutics

  1/4/2023

  Sesen Bio, Inc. (Nasdaq: SESN) today issued the following statement reiterating the Company’s confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. (Carisma) as the best path forward for stockholders.

• Sesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending Merger

  12/29/2022

  Sesen Bio, Inc. and Carisma Therapeutics Inc., a privately-held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced an amendment to their previously announced merger agreement dated September 20, 2022.